GH Research (GHRS) Stock Forecast & Price Target
$1.49B
Market Cap
-20.71
P/E
—
Forward P/E
67
Score
GHRS price $21.77 +1.06 +5.12%
Stocklytics score rationale: value 49, quality 52, growth 100.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has…
GHRS fair value Not meaningful. Price $21.77.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Not meaningful
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-05 | — | -0.31 | — | — |
| 2026-08-06 | -0.23 | -0.29 | — | — |
| 2026-05-14 | -0.31 | -0.27 | — | — |
| 2026-03-05 | -0.23 | -0.29 | — | — |
| 2025-11-06 | -0.23 | -0.23 | — | — |
| 2025-08-07 | -0.15 | -0.22 | — | — |
| 2025-05-08 | -0.19 | -0.61 | — | — |
| 2025-02-27 | -0.17 | -0.23 | — | — |
| 2024-11-14 | -0.23 | -0.25 | — | — |
| 2024-09-03 | -0.20 | -0.23 | — | — |
| 2024-05-03 | -0.15 | -0.22 | — | — |
| 2024-02-29 | -0.21 | -0.20 | — | — |
| 2023-11-09 | -0.11 | -0.20 | — | — |
| 2023-08-23 | -0.15 | -0.25 | — | — |
| 2023-05-11 | -0.21 | -0.22 | — | — |
| 2023-03-02 | -0.32 | -0.17 | — | — |
| 2022-11-10 | -0.01 | -0.17 | — | — |
| 2022-08-23 | 0.01 | -0.17 | — | — |
| 2022-05-18 | -0.11 | -0.16 | — | — |
| 2022-03-28 | -0.09 | -0.17 | — | — |
| 2021-12-06 | -0.04 | -0.10 | — | — |
| 2021-09-23 | -0.05 | -0.08 | — | — |
| 2021-06-28 | -0.02 | — | — | — |
| 2020-12-31 | -0.01 | — | — | — |
| 2020-09-30 | -0.00 | — | — | — |
| 2020-06-30 | -0.00 | — | — | — |
| 2020-03-31 | -0.00 | — | — | — |
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-09-08 | Schonharting Florian | Buy | 2.30K | $0.03 | 58 |
| 2026-08-11 | Moore Duncan | Buy | 2.20K | $0.03 | 55 |
| 2026-08-11 | Hanley Dermot John | Buy | 2.20K | $0.03 | 55 |
| 2026-08-11 | Forer Michael | Buy | 100.00K | $0.03 | 2.50K |
| 2026-08-11 | Forer Michael | Buy | 2.20K | $0.03 | 55 |
| 2026-04-01 | Schonharting Florian | Other | 0 | — | — |
| 2026-03-18 | Moore Duncan | Other | 0 | — | — |
| 2026-03-18 | Moore Duncan | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Cameron Aaron Luke | Other | 33.21K | $21.32 | 708.06K |
| 2026-03-18 | Cameron Aaron Luke | Other | 100.00K | $0.03 | 2.50K |
| 2026-03-18 | Cameron Aaron Luke | Other | 25.00K | $5.80 | 145.00K |
| 2026-03-18 | Hanley Dermot John | Other | 0 | — | — |
| 2026-03-18 | Hanley Dermot John | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Halle Magnus Clemensen | Other | 0 | — | — |
| 2026-03-18 | Halle Magnus Clemensen | Other | 50.00K | $0.03 | 1.25K |
| 2026-03-18 | Forer Michael | Other | 0 | — | — |
| 2026-03-18 | Forer Michael | Other | 4.67K | $0.03 | 117 |
| 2026-03-18 | Valcheva Velichka | Other | 50.00K | $10.83 | 541.50K |
| 2026-03-18 | Valcheva Velichka | Other | 35.00K | $7.59 | 265.65K |
| 2026-03-18 | Valcheva Velichka | Other | 300.00K | $0.03 | 7.50K |
| 2026-03-18 | Ryan Julie | Other | 50.49K | $12.32 | 622.00K |
| 2026-03-18 | Ryan Julie | Other | 30.00K | $0.03 | 750 |
Latest filed quarter: Q2 2026.
Institutions holding: 68, holders +13 vs prior quarter. Ownership 77.41%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| LYNX1 CAPITAL MANAGEMENT LP | 13.26M | 2.50M | +23.23% | 356.52M |
| BVF INC/IL | 8.65M | 0 | 0.00% | 232.52M |
| RA CAPITAL MANAGEMENT, L.P. | 7.64M | -39.88K | -0.52% | 205.28M |
| FMR LLC | 5.98M | 841.00K | +16.37% | 160.66M |
| RTW INVESTMENTS, LP | 5.93M | 0 | 0.00% | 159.50M |
| DEEP TRACK CAPITAL, LP | 3.33M | 3.33M | New | 89.60M |
| AVORO CAPITAL ADVISORS LLC | 1.80M | 0 | 0.00% | 48.38M |
| FORESITE CAPITAL MANAGEMENT VI LLC | 940.49K | 625.00K | +198.10% | 25.28M |
| JEFFERIES FINANCIAL GROUP INC. | 712.30K | 0 | 0.00% | 19.15M |
| BLACKROCK, INC. | 480.29K | 24.67K | +5.41% | 12.91M |
| UBS GROUP AG | 477.41K | 64.99K | +15.76% | 12.83M |
| MILLENNIUM MANAGEMENT LLC | 323.40K | -614.50K | -65.52% | 8.69M |
| BRAIDWELL LP | 207.24K | 207.24K | New | 5.57M |
| BOOTHBAY FUND MANAGEMENT, LLC | 202.10K | -80.79K | -28.56% | 5.43M |
| JANE STREET GROUP, LLC | 169.95K | 169.95K | New | 4.57M |
| HIGHVISTA STRATEGIES LLC | 158.77K | -54.44K | -25.53% | 4.27M |
| TREXQUANT INVESTMENT LP | 153.77K | 83.96K | +120.27% | 4.13M |
| GOLDMAN SACHS GROUP INC | 148.67K | 103.88K | +231.90% | 4.00M |
| XTX TOPCO LTD | 86.99K | 34.90K | +66.99% | 2.34M |
| CITADEL ADVISORS LLC | 85.95K | 85.95K | New | 2.31M |
| ADVISORSHARES INVESTMENTS LLC | 71.27K | 4.23K | +6.31% | 1.92M |
| CENTERBOOK PARTNERS LP | 69.44K | -147.14K | -67.94% | 1.87M |
| HRT FINANCIAL LP | 65.38K | 65.38K | New | 1.76M |
| MORGAN STANLEY | 52.22K | 26.39K | +102.16% | 1.40M |
| POINT72 ASSET MANAGEMENT, L.P. | 50.88K | 50.88K | New | 1.37M |
Consensus Buy from 10 analysts. Average price target $48.83, +124.3% versus the current price. Low $39.00. High $65.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $48.83 for GH Research (GHRS), 122.9% above the current price of $21.91. Of 10 analysts covering the stock, 10 rate it Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $39.00 |
|---|---|
| Average | $48.83 |
| High | $65.00 |
The average is 122.9% above the current price of $21.91.
Of 10 analysts, 10 rate GH Research Buy or Strong Buy, 0 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS -1.19, revenue $0. 2027, EPS -1.83, revenue $50.65 million.
The Stocklytics Score for GHRS is 67 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
$48.83 average, with a published range of $39.00 to $65.00.
The consensus is Buy from 10 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is -1.19. The average revenue estimate is $0.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: GH Research · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$1.49B
Market Cap
-20.71
P/E
—
Forward P/E
67
Score